298 related articles for article (PubMed ID: 12582019)
21. Assessment of preoperative serum prolidase activity in epithelial ovarian cancer.
Camuzcuoglu H; Arioz DT; Toy H; Kurt S; Celik H; Aksoy N
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):97-100. PubMed ID: 19695763
[TBL] [Abstract][Full Text] [Related]
22. Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage.
Harv Womens Health Watch; 2010 Apr; 17(8):1-3. PubMed ID: 20506601
[No Abstract] [Full Text] [Related]
23. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
24. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
25. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
27. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
28. Current clinical use of biomarkers for epithelial ovarian cancer.
Moore RG; Maclaughlan S
Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
[TBL] [Abstract][Full Text] [Related]
29. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients.
Choi JH; Oh JY; Ryu SK; Kim SJ; Lee NY; Kim YS; Yi SY; Shim KS; Han WS
Cancer; 1997 May; 79(10):1879-83. PubMed ID: 9149012
[TBL] [Abstract][Full Text] [Related]
30. Anthropometry and the risk of epithelial ovarian cancer.
Greer JB; Modugno F; Ness RB; Allen GO
Cancer; 2006 May; 106(10):2247-57. PubMed ID: 16596653
[TBL] [Abstract][Full Text] [Related]
31. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
32. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
33. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
34. [Early detection and preoperative diagnosis of ovarian carcinoma].
Kainz C
Wien Med Wochenschr; 1996; 146(1-2):2-7. PubMed ID: 8835487
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
[TBL] [Abstract][Full Text] [Related]
37. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer screening: a look at the evidence.
Fields MM; Chevlen E
Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
[TBL] [Abstract][Full Text] [Related]
39. How relevant are ACOG and SGO guidelines for referral of adnexal mass?
Dearking AC; Aletti GD; McGree ME; Weaver AL; Sommerfield MK; Cliby WA
Obstet Gynecol; 2007 Oct; 110(4):841-8. PubMed ID: 17906018
[TBL] [Abstract][Full Text] [Related]
40. Women's awareness of ovarian cancer risks and symptoms.
Lockwood-Rayermann S; Donovan HS; Rambo D; Kuo CW
Am J Nurs; 2009 Sep; 109(9):36-45; quiz 46. PubMed ID: 19704232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
